Recruiting

Trial ID CA119-0002 | NCT06153251

A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma

Summary

The purpose of this study is to assess BMS-986453 in participants with relapsed and/or refractory multiple myeloma (RRMM).

Participants must have a diagnosis of multiple myeloma with relapsed and/or refractory disease.
Participants must have confirmed progressive disease on or within 12 months (measured from the last dose) of completing treatment with the last anti-myeloma treatment regimen before study entry.
Participants in Part A and Part B Cohort 1 must have received at least 3 prior anti-myeloma treatment regimens, including a proteasome inhibitor and immunomodulatory agent.
Participants must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
Participants must have adequate organ function.

Participants must not have any known active or history of central nervous system (CNS) involvement of multiple myeloma.
Participants must not have active or history of plasma cell leukemia, Waldenstrom's macroglobulinemia, POEMS (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, skin changes) syndrome, or clinically significant amyloidosis.
Participants must not have a history or presence of clinically significant CNS pathology such as seizure disorder, aphasia, stroke, severe brain injury, dementia, Parkinson's disease, or cerebellar disease, or presence of clinically active psychosis. Other protocol-defined inclusion/exclusion criteria apply

Additional Information *

Study Arms

Experimental: Administration of BMS-986453

ASSIGNED INTERVENTION

Take the first step to see if you Match to a Clinical Trial – Check Your Eligibility

Check Your Eligibility

Answer some questions about Your health to see if you may match to this trial

Match to a Trial

If you are a match, click on the study to see the list of study site locations

Select a Study Site Location

Select a study site location that is convenient for you

Provide your contact details for the study site to connect with you.